Ohio is currently home to 3281 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults
Recruiting
The purpose of this clinical trial is to see if combining a licensed COVID-19 vaccine and a licensed influenza vaccine into a single shot is safe and can help produce antibodies to defend the body against both SARS-CoV-2 (the virus that causes COVID-19) and influenza. Participants enrolled in this trial will be healthy adults, 50 years of age or older.
Gender:
All
Ages:
50 years and above
Trial Updated:
02/20/2024
Locations: Centricity Research Columbus Ohio Multispecialty, Columbus, Ohio
Conditions: Influenza, Human, SARS-CoV-2 Infection, COVID-19
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center inpatient study to evaluate the efficacy and safety of LB-102 in adult patients diagnosed with acutely exacerbated schizophrenia. To determine whether LB-102 administered to patients with acutely exacerbated schizophrenia demonstrates antipsychotic efficacy, as determined by a change from Baseline on the Positive and Negative Syndrome Scale (PANSS) total score, compared to placebo at 28 days. The secondary objectives o... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/20/2024
Locations: Midwest Clinical Research Center, Dayton, Ohio
Conditions: Schizophrenia
A Post-Market Study for Long-Term Effectiveness and Safety of the NTX100 for RLS
Recruiting
Multi-center post-market, observational study to assess the long-term effectiveness and safety of the NTX100 TOMAC System for patients with Restless Legs Syndrome.
Gender:
All
Ages:
21 years and above
Trial Updated:
02/20/2024
Locations: Ohio Sleep Medicine and Institute, Dublin, Ohio
Conditions: Restless Legs Syndrome
Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)
Recruiting
This is a phase II double-blind, placebo-controlled study of artesunate ointment for the treatment of HPV-associated vulvar HSIL (usual type vulvar intraepithelial neoplasia 2/3).
Gender:
Female
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Cleveland Clinic Fairview Hospital, Cleveland, Ohio
Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
Recruiting
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of: A screening and placebo run-in period of approximately 2 weeks prior to first dosing Three treatment periods of approximately 4 weeks each (one period for ea... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
02/20/2024
Locations: Research Site, Grove City, Ohio
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Study of INKmune in Patients With mCRPC (CaRe Prostate)
Recruiting
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The study will consist of two stages.
Gender:
Male
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Carl & Edyth Lindner Center for Research and Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati, Ohio
Conditions: Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
Recruiting
The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: Multiple Myeloma
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
Recruiting
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: University Hospitals Seidman Cancer Center, Cleveland, Ohio
Conditions: Leukemia, Myeloid, Acute
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
Recruiting
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
Gender:
All
Ages:
Between 12 years and 18 years
Trial Updated:
02/20/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Single Ventricle Heart Disease
STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease
Recruiting
The goal of this clinical trial is to learn about the safety, pharmacokinetics and pharmacodynamics of AGMB-129 in patients with Crohn's disease. The main questions it aims to answer are: is AGMB-129 safe and well tolerated in these patients? what does the body do to the drug (pharmacokinetics)? what does the drug do to the body (pharmacodynamics)? The participants will be in the study for a total duration of up to 19 weeks, including a 5-week screening period, a 12-week double-blind, placebo-... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Fibrostenotic Crohn's Disease
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Recruiting
This study is researching an investigational drug called fianlimab (also called REGN3767) with two other medications called cemiplimab and chemotherapy, individually called a "study drug" or collectively called "study drugs". 'Investigational' means that the study drug is not approved for use outside of this study by any Health Authority. Examples of chemotherapy drugs include the following: Paclitaxel plus carboplatin, and Pemetrexed plus cisplatin. The study is being conducted in patients who... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/20/2024
Locations: Gabrail Cancer Center Research, Canton, Ohio
Conditions: Non-small Cell Lung Cancer
A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis
Recruiting
The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis (RMS) (Part 1), and to evaluate the effects of BIIB091 combination therapy with Diroximel Fumarate (DRF) compared with the DRF monotherapy arm, on the key Magnetic Resonance Imaging (MRI) measure of active Central Nervous System (CNS) inflammation (Part 2). The secondary objectives are to evaluate the effects of BIIB091 monotherapy on the MRI measures of... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
02/20/2024
Locations: The Boster Center for Multiple Sclerosis, Columbus, Ohio
Conditions: Relapsing Forms of Multiple Sclerosis